Published Jul 30, 2026, 11:11 AM EDT
Nine out of 12 former soldiers saw their symptoms improve after treatment with psilocybin, the main ingredient in magic mushrooms.
Veterans with hard-to-treat PTSD have seen major improvements in their symptoms, thanks to a trial of a new psychedelic therapy treatment involving the drug psilocybin—a controlled substance and the main ingredient in magic mushrooms. Researchers as part of a clinical trial treated 12 former soldiers suffering with PTSD using psilocybin and found that after a month of treatment, nine of the 12 veterans in the trial no longer met the criteria for PTSD, according to the pilot study published July 30 in Communications Medicine. The study was conducted by researchers at the Center for Psychedelic Drug Research and Education at Ohio State University. The latest results come on the heels of President Donald Trump giving the green light earlier this year, by way of an April executive order, calling on the U.S. Food and Drug Administration (FDA) to facilitate access to psychedelic drugs, including ibogaine compounds, psilocybin, ketamine, LSD and MDMA, for eligible patients suffering from major depressive disorder and substance abuse disorders. “For a population with severe treatment-resistant PTSD, these results are striking,” study co-author Stacey Armstrong, who is also of Ohio State University, said in a statement.
